Carl Zeiss Meditec AG
XETRA:AFX
Net Margin
Carl Zeiss Meditec AG
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| DE |
|
Carl Zeiss Meditec AG
XETRA:AFX
|
5.3B EUR |
7%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
234.9B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
183.6B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
147.5B USD |
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
144.2B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
111.9B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
51.2B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
49.4B USD |
7%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.2B USD |
75%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
42.2B USD |
23%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
287.7B CNY |
31%
|
Carl Zeiss Meditec AG
Glance View
Carl Zeiss Meditec AG stands as a beacon in the realm of medical technology, carving a niche through its innovative solutions in ophthalmology and microsurgery. Rooted in the prestigious legacy of the Zeiss Group, this company seamlessly fuses cutting-edge technology with practical medical applications. Its headquarters in Jena, Germany, serve as the crucible for pioneering research and development endeavors, channeling expertise into products that enhance both diagnostic and surgical capabilities. The heart of its operations revolves around creating technological marvels such as optical coherence tomography (OCT) instruments and surgical microscopes, which bring precision and enhanced clarity to the medical field. Through a well-executed blend of R&D and strategic acquisitions, Carl Zeiss Meditec consistently remains at the forefront of medical innovation, ensuring it meets the ever-evolving needs of the healthcare sector. Financially, the company thrives by selling its sophisticated medical devices directly to healthcare professionals, hospitals, and clinics worldwide. Rather than merely creating instruments, Carl Zeiss Meditec's business model is deeply entwined with providing comprehensive workflow solutions and service support, ensuring that medical practitioners extract maximum utility from their investments. By offering not just products but also extensive after-sales service and maintenance, the company builds sustained relationships with its clients, fostering a cycle of trust and repeat business. In addition, its engagement in training and support services enhances user competencies, ensuring the seamless integration of its technology into everyday medical practice and underscoring its commitment to elevating healthcare standards globally. Through this multifaceted approach, Carl Zeiss Meditec solidifies its position as an indispensable ally in the medical community, both as a supplier of state-of-the-art equipment and as a provider of essential healthcare solutions.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Carl Zeiss Meditec AG's most recent financial statements, the company has Net Margin of 7.2%.
You don't have any saved screeners yet